Find Clinical Trials

Inclusion Criteria: * Confirmed diagnosis of mild or moderate persistent, non-severe asthma. * Poorly controlled asthma, defined as an Asthma Control Test (ACT) score below 20. * Active inhaled maintenance therapy with inhaled corticosteroids (ICS), alone or combined with a long-acting beta-agonist (LABA). * Age 18 years or older. * Active follow-up in the Pulmonology outpatient clinic of Hospital Clínico San Carlos. * Sufficient cognitive capacity to participate and complete the questionnaires. * Access to a means of communication (in-person, telephone, digital, or mixed). * Signed informed consent. Exclusion Criteria: * Significant respiratory comorbidity (chronic obstructive pulmonary disease ( COPD), bronchiectasis, pulmonary fibrosis, chronic pulmonary thromboembolism, or home oxygen therapy). * Acute asthma exacerbation within the 4 weeks before inclusion. * Participation in another clinical trial within the previous 12 months. * Cognitive impairment or language barriers preventing completion of the questionnaires. * Conditions limiting continuity of follow-up over the 12 months. * Mild comorbidities such as allergic rhinitis or mild sleep apnea are not exclusion criteria.

Inclusion Criteria: * Common Inclusion Criteria: * Adults aged over 18 years, of both sexes * Patients eligible for or affiliated with a social security scheme * Patients who have provided written informed consent to participate in the study Common Exclusion Criteria: * Inability to give informed consent * Persons under legal protection (guardianship, trusteeship, or court protection) * Language barrier or psychological refusal to read the information * Medical conditions with a life expectancy \< 1 year according to clinical judgment * Ongoing participation restriction due to another clinical research study * Pregnant women (due to physiological hemodynamic changes in blood pressure and arterial stiffness during pregnancy) * Cardiac arrhythmias: current atrial fibrillation or high-degree atrioventricular block Exclusion Criteria: * Hypertension Group * Inclusion: Prior diagnosis of arterial hypertension * Stable cardiovascular treatment in the previous 1 month * Exclusion: * CKD with GFR \<60 mL/min * ACR \> 30 mg/mmol * Type 2 diabetes Type 2 Diabetes Group * Inclusion: * Prior diagnosis of type 2 diabetes * Stable cardiovascular treatment in the previous 1 month * Exclusion: * CKD with GFR \< 60 mL/min * ACR \> 30 mg/mmol Moderate CKD Group * Inclusion: * Moderate CKD (eGFR between 30 and 60 mL/min) (CKD-EPI) * Patients scheduled for arterial stiffness assessment as part of routine care * Stable cardiovascular treatment in the previous 1 month * Exclusion: * No specific exclusion criteria beyond common exclusions Severe CKD Group * Inclusion: * Severe CKD (GFR \< 30 mL/min for ≥ 2 months) * Patients scheduled for arterial stiffness assessment as part of routine care * Stable cardiovascular treatment the previous 1 month * Exclusion: No specific exclusion criteria beyond common exclusions20 / 48 C25-07\_Protocole\_ V1.0\_01.12.2025 Healthy Volunteers Group * Inclusion: No documented chronic disease * Exclusion: * Moderate or severe CKD (GFR \< 60 mL/min) (CKD-EPI) * Hypertension * Type 2 diabetes * Stable cardiovascular treatment in the previous 1 month

Inclusion Criteria: * Current PGY4 anesthesiology resident at Massachusetts General Hospital or Brigham and Women's Hospital * Willingness to provide informed consent Resident Loved One Inclusion Criteria * The choice of a resident loved one will be at the discretion of the resident. * This may include partners, family, friends or other loved ones. * Only one individual per resident will be eligible to participate. * Residents will be eligible to participate even if no loved one is identified. Exclusion Criteria: * Inability to complete English-language questionnaires * Inability to access and use the intervention components (smartphone app/web platform) * Age \<18 years * Concurrent participation in another interventional study designed to target mental fitness or wellbeing

Inclusion Criteria: * self-identify as LGBTQ+ * 18 years old or older * live in the USA or territories * speak and understand English * Currently pregnant or within one year of childbirth * Endorse current mild depressive symptoms or risk factors for postpartum depression Exclusion Criteria: * Are unable to consent/have impaired decision making capacity * Have current active suicidal or homicidal ideation, active psychosis, or current mania * Are currently experiencing a severe depressive episode * Do not have audio and/or video capacity for attending group sessions remotely.

Inclusion Criteria: * Women diagnosed with breast cancer, stage 0, I, or II, * Having undergone mastectomy, and at least 6 months having passed since the completion of radiotherapy and chemotherapy treatment, * Aged 18-49, not pregnant, not breastfeeding, not menopausal, * Women with sexual dysfunction (FSFI score 26.55 or lower), sexually active, married and living with their spouse. Exclusion Criteria: * Women with chronic, psychological, and physical illnesses, * Those with alcohol and substance abuse, * Those who have previously received education or counseling for sexual dysfunction, * Women diagnosed with cancer other than breast cancer

Inclusion Criteria: * Active enrollment in the Faculties of Medicine, Nursing, Pharmacy, Dentistry, or Psychology at Istanbul Nisantasi University * Aged between 18 and 25 years * Provision of voluntary digital informed consent Exclusion Criteria: * Currently receiving active psychiatric treatment (psychotherapy or pharmacotherapy) * Change in psychopharmacological medication within the past 6 months * Prior reading of either of the study books * Presence of acute psychotic symptoms or suicidal risk

Inclusion Criteria: * fluent in written and spoken Finnish or Swedish * access to computer or mobile phone with internet * between 12 and 22 weeks pregnant * screening and baseline score on the EPDS ≥10 points Exclusion Criteria: * lifetime history of psychotic disorder (e.g. schizophrenia, schizoaffective disorder, bipolar disorder, psychotic depression) * active suicidal ideation * severe substance abuse or dependence * participates in another intervention study aiming at treating the symptoms of antenatal depression

Inclusion Criteria: * Adults over 18 years old * Adults who meet one of the following criteria: a physician's diagnosis of asthma; coded as asthma (R96) as per the international classification of primary care (ICPC) or international classification of diseases (ICD) code J45 with associated use of asthma medications for 6 months prior to study enrolment. Exclusion Criteria: * Adults under 18 years old * Adults with no diagnosis of asthma * Adults receiving asthma education in a specialist hospital or community setting * Adults unable to give informed consent * Smoking ≥ 10 Pack Year History

Inclusion Criteria: 1. Written informed consent obtained. 2. Adult patients aged ≥ 18 years. 3. Patients with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors, who have disease progression following standard-of-care therapy, are intolerant to standard treatment, or have no available standard treatment options (e.g., HR+/HER2- breast cancer, Cyclin E1-overexpressing solid tumors and other solid tumors). 4. Agree to provide available archived FFPE tumor tissue specimens or voluntarily accept pre-treatment tumor biopsy (Phase Ⅱ). 5. Have RECIST 1.1-defined measurable lesions. 6. Has a life expectancy of \> 3 months. 7. ECOG performance status 0-1. 8. Adequate marrow, liver and kidney function. 9. Meet the study's specified contraceptive requirements. Exclusion Criteria: 1. Have a second primary malignancy. 2. Patients with primary CNS tumors or CNS metastases with prior local treatment failure. 3. Have received any anti-tumor therapy or participated in other therapeutic clinical trial within 28 days prior to the first dose of study drug. 4. Has undergone major surgery within 28 days prior to the first dose of study drug. 5. Prior anti-tumor therapy-related toxicities have not recovered to protocol-specified grades. 6. Diagnosed with immunodeficiency or received any form of immunosuppressive therapy within 7 days prior to the first dose. 7. Patients with other severe and persistent underlying medical conditions as assessed by the Investigator. 8. Have protocol-defined clinically significant cardiovascular diseases. 9. Prolonged QTcF interval. 10. Have any medical conditions likely to impair digestion and absorption of the investigational product. 11. Patients with poorly managed blood glucose levels and blood pressure. 12. Clinically significant abnormal serum potassium or sodium as judged by the investigator. 13. Have experienced a severe concurrent infection 14 days prior to the first dose of study drug. 14. Confirmed infection with HIV, HBV or HCV. 15. Are currently receiving any other investigation agent. 16. Have received prior CDK2 inhibitors. 17. Patients with known hypersensitivity to the study drug or any of its components. 18. History of allogenic tissue or solid organ transplant. 19. Are unwilling or unable to comply with procedures required in this protocol. 20. Has other severe systemic diseases or for other reasons deemed ineligible for participation in this clinical trial by the investigator.

Inclusion Criteria: * Patient meets the diagnostic criteria for T1DM recommended by WHO and is diagnosed with T1DM. * Patient was diagnosed with T1DM for \>= 6 months. * Patient has no cognitive or awareness disorders and has the ability to read. * Patient agrees to participate in this study. * Patient's family caregiver has a certain level of comprehension ability, is conscious and clear-minded during the survey, and can answer freely. * Patient's family caregiver voluntarily participates in the survey. * Patient's family caregiver provides an average daily care time for the child of \>= 6 hours. Exclusion Criteria: * Patient has acute or chronic complications of diabetes and is unable to cooperate, requiring urgent treatment. * Patient is in a state of disease stress, such as acute infection, surgery, trauma, etc., and is difficult to cooperate with the research. * Patient's family caregiver has unconsciousness or abnormal mental state. * Patient's family caregiver has hearing or language disorders. * Patient or patient's family caregiver has already participated in this survey.

Inclusion Criteria : * Pregnant women between 30-33 weeks of gestation * Primiparous * Age 18 years and above * Able to read and communicate in the local language * Living with a partner Exclusion Criteria: * History of diagnosed psychiatric illness (e.g., bipolar disorder, schizophrenia) * High-risk pregnancy conditions that require specialized medical care * Unwilling or unable to commit to the intervention schedule

Inclusion Criteria: * Resident in Region Uppsala, Sweden * Turning 50, 55, 60, 65, 70 or 75 years during recruitment period * Able to provide informed consent Exclusion Criteria: * Inability to provide informed consent * Protected identity

Inclusion Criteria: Healthy adult part 1. Japanese healthy adult male subjects 2. Age at the time of informed consent: 18 to 45 3. BMI (at screening): 18.5 kg/m2 to less than 25.0 kg/m\^2 Chronic kidney disease patient part 1. Chronic kidney disease patients with type 2 diabetes mellitus 2. Age at the time of informed consent: 18 to less than 65 3. UACR measured by 24-hour urine collection: 300 mg/g to less than 3500 mg/g Exclusion Criteria: Healthy adult part 1. Subjects who currently receive treatment for or have a history of any of the following diseases: respiratory system, cardiovascular system, psychiatric system, nervous system, gastrointestinal system, immune system, liver, kidney, hematopoietic function, or endocrine function. 2. Presence or history of severe allergy to drugs or food 3. Presence or history of drug or alcohol dependence Chronic kidney disease patient part 1. Current symptoms of severe, progressive, or uncontrolled hepatic, hematologic, gastrointestinal, pulmonary, psychiatric, cardiac, endocrine, neurologic, or cerebral disease 2. Patients with type 1 diabetes mellitus 3. Patients with a history of dialysis treatment

Inclusion Criteria: * Primary DSM-5 diagnosis of current MDD. * The duration of the current MDE must be between 6 weeks and 18 months. * Without psychotic or catatonic features. * Capable of reading and understanding English and able to provide written informed consent to participate. Exclusion Criteria: * Diagnosis of DSM-5-defined lifetime bipolar disorder (I, II, or unspecified), schizophrenia, schizoaffective disorder, MDD with psychotic features, other psychotic disorder, or antisocial personality disorder; current (past month) obsessive-compulsive disorder; current (past month) posttraumatic stress disorder; current (past 3 months) anorexia nervosa, * Diagnosis of borderline personality disorder that is known, suspected * Participants with comorbid generalized anxiety disorder (GAD), social anxiety disorder (SAD), or panic disorder are excluded only if the GAD, SAD, or panic disorder is considered the primary psychiatric diagnosis, rather than MDD. * Participants with treatment refractory MDD, ie, previously having failed in their lifetime ≥2 treatments (due to inadequate efficacy) with at least 2 different classes of antidepressants of adequate dose, duration, and treatment adherence. * History of substance use disorder and/or alcohol use disorder during the preceding 12 months * Use of antidepressants (including ketamine/esketamine, St. John's Wort, S-adenosyl methionine, and/or trazodone used as an antidepressant) within 4 weeks of Baseline (Visit 2), except for fluoxetine, which must not be within 6 weeks of Baseline (Visit 2)

Inclusion Criteria: * Pregnant women aged 18 years or older * Gestational age below 25 weeks at recruitment * Able to communicate in Chinese and provide informed consent * Willing to participate in the study and complete follow-up assessments Exclusion Criteria: * Diagnosed epilepsy, photosensitive epilepsy, or other neurological disorders * Severe anxiety, depression, or other psychiatric disorders currently receiving intensive treatment * History of severe adverse reactions to virtual reality devices, including severe dizziness, nausea, or visual discomfort * Inability to participate in mindfulness or VR intervention proceduresriteria: Exclusion Criteria: \-

Inclusion Criteria: * Age between 18 and 75 years. * Confirmed diagnosis of type 2 diabetes mellitus with SCORE2-Diabetes risk score \>10%. * Stable angina pectoris. * Coronary CT angiography (CCTA) demonstrating 50%-90% stenosis in at least one coronary vessel with diameter ≥2.5 mm. * CT-derived fractional flow reserve (CT-FFR) \>0.8 in the target vessel. * Stable standard therapy for diabetes and cardiovascular disease, with no changes in SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors within the past 4 weeks. * Able and willing to provide written informed consent. Exclusion Criteria: * History of coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI) with stenting, prosthetic valve replacement, or permanent pacemaker implantation. * New York Heart Association (NYHA) functional class III or IV heart failure. Acute myocardial infarction within the previous 30 days. * Known allergy to iodinated contrast media or other contraindications to CCTA. Severe arrhythmia or coronary artery calcium (CAC) score \>400. * Estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73 m². History of serious adverse reactions to SGLT2 inhibitors. * Pregnancy, lactation, or planned pregnancy during the study period. Severe liver dysfunction (Child-Pugh class C). * Any other condition that, in the investigator's opinion, makes the participant unsuitable for the trial.

Inclusion Criteria: 1. Age ≥19 years 2. Idiopathic SSNHL: ≥30 dB sensorineural hearing loss across ≥3 consecutive frequencies within 72 hours 3. Affected ear PTA4 (mean of 0.5/1/2/4 kHz) ≥40 dB HL (moderate or greater) 4. Planned methylprednisolone 48 mg/day orally once in the morning 5. At least one of: known T2DM; HbA1c 5.7-10.0% within 3 months; POC glucose ≥140 mg/dL ×2 (≥2h apart, ≥1 postprandial) within 24h of steroid 6. If on prior insulin: outpatient TDD ≤30 U/day 7. Able to eat ≥2 meals/day, wear CGM and patch pump, use smartphone 8. Willing to undergo 2-night inpatient admission (Day 1-3) 9. Written informed consent Exclusion Criteria: 1. Type 1 DM, LADA, pancreatogenic DM, DKA/HHS within 12 months, ketonuria at enrollment 2. Enrollment POC ≥350 mg/dL or immediate IV insulin requirement 3. HbA1c ≥10.0% 4. eGFR \<30 mL/min/1.73m² or dialysis 5. Pregnancy/breastfeeding; women of childbearing potential: positive urine hCG 6. ICU, sepsis, NPO, TPN/enteral nutrition 7. Severe hepatic failure (Child-Pugh C) 8. Dexamethasone, divided-dose, or pulse steroids planned 9. Prior CSII or AID device user 10. Skin adhesive allergy precluding CGM or patch pump use 11. Insufficient cognitive function for device or dosing table use 12. Planned MRI requiring repeated CGM/pump removal 13. PTA \>70 dB (profound hearing loss requiring combined intratympanic steroid)

Inclusion Criteria: * Diagnosed with major depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), by two independent psychiatrists * 24-item Hamilton Depression Rating Scale (HAMD-24) total score greater than 20 at baseline * Aged 18 to 65 years * Right-handed * Able to understand the study procedures and willing to provide written informed consent Exclusion Criteria: * History of epilepsy, brain tumor, or brain trauma * Receipt of transcranial magnetic stimulation, transcranial electrical stimulation, or electroconvulsive therapy within the past 3 months * Presence of metal implants or other contraindications to transcranial electrical stimulation or magnetic resonance imaging * Acute or severe suicidal ideation * Any other condition judged by the investigators to make participation unsuitable for this study

Inclusion Criteria: * Women with histologically confirmed epithelial breast cancer * Age \>18 years * Pathological stage * Eastern Cooperative Oncology Group performance status 0-1 * Normal cardiac function and adequate bone marrow, hepatic and renal function.

Inclusion Criteria: 1. Aged \> 18 years of age 2. Patients undergoing lumbar surgery for degenerative disc disease or spinal stenosis involving two or more levels 3. Montreal Cognitive Assessment (MoCA) score ≥ 18 - accept mild 4. Ability to use a keyboard 5. Able to understand and communicate in English 6. Be able to consent independently 7. Women of child-bearing age must be comfortable confirming a negative pregnancy prior to participating in the study. 8. Must not be involved in any other research intervention study testing neurobehavioral functioning Exclusion Criteria: 1. Age \< 18 years of age 2. History of vagotomy (cutting the vagus nerve) 3. History of bradycardia, heart block, prolonged QT syndrome, brugada syndrome, heart failure with ejection fraction less than 35% and/or New York Heart Association symptoms 4. MoCA \< 18 5. History of seizure disorder or intracranial hemorrhage 6. Patients with carotid stenosis 7. Patients with aneurysms 8. Other neurological diagnoses or a diagnosis of severe psychiatric disorder (e.g., psychosis) or a reported childhood learning disability 9. Pregnancy, breastfeeding 10. Active addiction history 11. ECG adhesive allergy 12. Severe aphasia, preventing subject from understanding the protocol and giving written consent 13. Patients will be excluded postoperatively if there is neck swelling at the proposed site of left tcVNS.